We demonstrate here the crucial role of MCL-1 and BCL-xL in ER+ breast cancer, reinforcing the possible therapeutic use of BH3 mimetic combinations for this type of cancer to avoid patient relapse. This evidence concerns the gene BCL2L1 and breast carcinoma.